Shanghai Institute of Hematology;
State Key Laboratory of Medical Genomics;
Collaborative Innovation Center of Hematology;
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine;
Shanghai 200025;
China;
Shanghai Institute of Hematology;
State Key Laboratory for Medical Genomics and Department of Hematology;
Collaborative Innovation Center of Systems Biomedicine;
Pôle SinoFrançais des Sciences du Vivant et Genomique;
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine;
Shanghai 200025;
China;
Research Center for Experimental Medicine;
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine;
Shanghai 200025;
China;
The School of Medicine;
Hangzhou Normal University;
Hangzhou 310036;
China;
Shanghai Institute of Hypertension;
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine;
Shanghai 200025;
China;
hemophilia A; adeno-associated virus(AAV); human/rat hybrid factorⅧ; gene therapy; dual chain strategy;